Introduction: Psoriatic arthritis (PsA) is underdiagnosed and has a substantial impact
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease, with symptoms that typically include swelling and pain in the peripheral joints, enthesitis, and dactylitis. The clinical presentation of PsA varies. It occurs in approximately 30% of patients with psoriasis [4, 12, 16, 25, 28] and typically follows the onset of psoriasis by approximately 8-10 years [12, 22] .
Nail involvement typically occurs more often and is more severe in patients with PsA than in those with psoriasis alone and may predict the development of PsA in patients with psoriasis [10, 12, 16, 20, 24, 30, 35] .
The burden of ongoing skin and joint inflammation characteristic of PsA is often overwhelming. In particular, the disease negatively affects quality of life (QoL) and work productivity, and leads to high rates of health-care utilization [4, 24, 32, 33] . Patients with PsA report reduced QoL and have more work-related problems, health-care visits, and hospitalizations than patients with psoriasis alone [4] . The progression of joint disease is associated with greater disability, and QoL sharply declines as limitations in daily activities increase [24, 32] . Likewise, PsA is associated with increased medical costs and loss of work productivity as the level of severity increases [4] . In addition, evidence suggests that persistent systemic inflammation fosters and worsens the severity of other co-morbidities, such as obesity and heart disease [4, 6, 11, 15] .
The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP), a population-based survey of 3426 patients and nearly 781 physicians in North America and Europe, is the largest probability survey of psoriatic disease conducted to date [22, 23, 34] . Here, we explore the results compiled from the subset of patients with PsA participating in the MAPP survey. We hypothesized that PsA would have a substantial impact on disease burden in the subset of patients with PsA in the MAPP survey.
METHODS
Abt SRBI, Inc. (New York, NY, USA) conducted the MAPP survey between June and August 2012 [22] . Via telephone, Abt SRBI staff surveyed households in the USA, Canada, France, Germany, Italy, Spain, and the UK. The MAPP survey followed the American Association for Public Opinion Research guidelines for developing and conducting surveys [1] . Institutional review board approval was granted for data collection in the USA (Abt SRBI 5454), and the other countries abided by standards and ethical practices according to their codes or guidelines.
Random digit dialing was performed to provide a probability sample, and participants were invited to complete the survey if they were C18 years of age and were ever diagnosed with psoriasis and/or PsA by a health-care provider (HCP). The survey questions used have been published previously [22] Table 1 .
RESULTS

Patients and Disease History
A total of 139,948 households were screened, and 3426 patients agreed to participate in the MAPP survey. Of the overall MAPP patient population, 712 respondents (21%) reported a diagnosis of PsA. The mean age of the patients with PsA was 56 years, the majority were female, and nearly three-quarters reported being overweight (33.6%) or obese (36.4%; Table 2 ).
Co-morbidities were common in patients with PsA, with arthritis (unspecified), hypertension, depression, diabetes, and heart disease reported most often. The average age of patients at the time of PsA diagnosis was 42 years, with an average delay between the onset of joint symptoms and diagnosis of PsA of 5 years.
Most patients with PsA (72%) developed skin signs and symptoms first, but 21% reported that they had joint signs and symptoms first, and 7%
reported that skin and joint signs and symptoms appeared concurrently. PsA was diagnosed on average 8 years after psoriasis; 27% of the surveyed patients reported that they were diagnosed with psoriasis and PsA at the same time. Bend down to pick up clothing from the floor?
Turn faucets on and off?
Get in and out of the car?
Current Symptoms
At the time of the survey, 88% of patients reported current joint pain or soreness; of these, 60% reported that more than four joints were affected (Fig. 1a) . Of the patients reporting joint pain, 41% had knee pain, 26% had finger pain, 19% had hip pain, 19% had ankle pain, 18%
had back pain, and 16% had wrist pain. In all, 31% of patients reported symptoms resembling enthesitis (i.e., pain/swelling of heel), and 45% reported symptoms resembling dactylitis (i.e., having ''sausage'' digits). In addition, patients reported itching (62%), scales (58%), flaking (58%), redness (58%), and pain (51%) associated with psoriasis lesions. Nail symptoms were present in nearly twice as many patients with PsA (21%) compared with patients with psoriasis alone (11%). Scalp involvement was reported by 44% of patients with PsA and 48%
with psoriasis alone.
Self-perceived Severity
Patients were asked to rate their disease severity at its worst on a scale of 1 (very mild) to 10 (very severe). More than half of the patients with PsA (53%) rated their disease as severe (score: 8-10), 35% rated their disease as moderate (score: 4-7), and 12% rated their disease as mild (score: 1-3; Fig. 1b ). In comparison, 27% of psoriasis patients rated their disease as severe [22] . As expected, the most important factor affecting self-perceived severity in patients with PsA was pain or swelling of the joints (45%); other commonly reported factors included itching (18%), location and size of skin lesions (10%), and lack of sleep (7%).
Impact on Physical Function: the HAQ-8
The proportions of PsA patients answering ''with much difficulty'' or ''unable to do'' on the eight-item Health Assessment
Questionnaire (HAQ-8 or modified HAQ [27] ) progressively increased for those with more than four affected joints and those with symptoms resembling enthesitis or dactylitis; Fig. 2a) . Likewise, the proportions of patients with PsA answering ''with much difficulty'' or ''unable to do'' increased for most questions in patients with higher palm counts (Fig. 2b) , 
Employment Status and Work Impact
PsA severely impacted patients' work productivity (Fig. 3) . Nearly one-third of patients with PsA (31.5%) reported that they had missed work in the past 12 months because of their disease. Similarly, 31.6% reported that PsA had impacted their ability to work full time.
Approximately one-quarter of patients with PsA reported ''a lot'' or ''some'' impact of their disease on getting a job, keeping a job, and choice of career. These results are consistent with survey results of patients with psoriasis, which found that patients with psoriasis were significantly more likely to miss work time and to experience impairment while working compared with controls [36] .
Medical Care and Treatment
In all, 83% of patients visited an HCP in the past 12 months for PsA, and 71% were evaluated by a rheumatologist at some point since their diagnosis. Moreover, they were followed specifically for PsA by different types of physicians: rheumatologist (37%), primary care provider (28%), and dermatologist (24%). When analyzed by country, the proportions of patients seen by rheumatologists for PsA ranged from 26% in Germany to 53% in Italy and Spain, and the proportions of patients seen by dermatologists for PsA ranged from 13% in the UK to 46% in Germany. Those patients who had not visited an HCP in the past 12 months reported that they did not believe an HCP could help (30%), their symptoms were not bad enough (30%), symptoms were absent (20%), current treatment was working (7%), and cost-or insurance-related issues were a factor (5%).
Current Treatment
More than half of the patients with PsA (59%)
reported that they were receiving no treatment or topical therapy only and were not receiving any systemic medication for their joint disease. Overall, the proportions of patients with PsA who reported current treatment were 31% for topical therapy only, 19% for conventional oral therapy, 14% for biologic therapy, and 8% for the combination of oral and biologic therapy. 
Treatment Burden
Conventional Oral Therapy (DMARDs)
More than 50% of patients who had received oral DMARDs found it to be burdensome, with one-third of patients reporting that the therapies were very or moderately burdensome. The most common reason patients found oral DMARDs burdensome was side effects; other reasons included the need for laboratory monitoring (Fig. 4a) . Methotrexate was the oral DMARD most commonly reported as current therapy (n = 100), and 34% of patients reported it as ''very burdensome.'' The most common reasons patients found methotrexate burdensome were side effects (69%) and need for laboratory monitoring (26%). The most common reasons patients discontinued conventional oral therapy were lack or loss of effectiveness and lack of tolerability (Fig. 4b) .
Biologic Therapy
Among patients who received injectable biologic therapy, 54% found it to be burdensome, with nearly one-third reporting that these medications were very or moderately burdensome. The most common reasons patients with PsA found biologic therapy burdensome were side effects (25.8%), fear of injections (22.7%), and inconvenience (9.1%; Fig. 4c ). Adalimumab and etanercept were the injectable biologics most commonly reported as current therapy. The most common reasons patients with PsA discontinued biologic therapy included lack or loss of effectiveness and cost or insurance issues (Fig. 4d) .
Overall, 64% of patients with PsA expressed concern about the health risks associated with long-term therapy, and 90% of patients with PsA felt there was a need for better therapies for psoriasis and PsA.
DISCUSSION
The MAPP survey is the largest multinational probability survey of patients with psoriasis and PsA to date [22, 23, 34] . PsA was reported in 21% of the overall MAPP patient population, which is generally consistent with published prevalence estimates [4, 12, 16, 25, 28] .
PsA was likely present, but undiagnosed in a proportion of psoriasis patients. In the global MAPP findings for psoriasis patients without a diagnosis of PsA (n = 2714), 44%
reported pain or soreness in any joint, 16% reported symptoms resembling enthesitis, and 26% reported symptoms resembling dactylitis [22] . Although a number of conditions may be associated with joint pain, previous studies have shown that a high proportion of patients have undiagnosed PsA [2, 14, 28] . Symptoms resembling enthesitis (i.e., pain/ swelling of heel) were reported by 31% of patients, and symptoms resembling dactylitis (i.e., ''sausage'' digits) were reported by 45% of patients. Enthesitis and dactylitis, important distinguishing features of PsA in many patients, are associated with more severe disease; both can be difficult to treat and can lead to disability [5, 13, 31] . Approximately twice as many patients with PsA (21%) had nail involvement compared with patients with psoriasis alone (11%), and 44% of patients with PsA reported scalp involvement; however, overall these rates are lower than those previously reported [8, 17, 18, 21, 26] . The presence of skin disease in these areas has been found to have a disproportionate effect on QoL and is often difficult to treat, with limited effective treatment options [7, 9, 19, 21] .
Lastly, co-morbidities, including unspecified arthritis, hypertension, depression, diabetes, and heart disease, were commonly reported by patients with PsA, as was obesity.
This finding is consistent with prior reports of a higher prevalence of cardiovascular disease and associated risk factors, such as diabetes and other chronic diseases, in patients with PsA compared with psoriasis patients or matched controls in the community [4, 6, 11, 15] . The multiple co-morbidities, often present in a single patient, complicate the selection of therapeutic agents due to safety concerns and create challenges in the assessment of the functional impact of PsA.
Patients diagnosed with PsA were more likely to be treated compared with patients with psoriasis only [22] ; however, many patients with PsA remain untreated or undertreated. 
CONCLUSIONS
The MAPP survey results underscore the substantial disease burden associated with PsA and the significant impact on physical function.
Survey results suggest undertreatment of PsA as well as a high rate of treatment burden.
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